Related Experiment Video
Updated: Jun 24, 2026
10:58
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Blimp1 is limiting for transformation in a mouse plasmacytoma model
Kathy D'Costa1, Dianne Emslie, Donald Metcalf
1Division of Immunology, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
Blood
|March 31, 2009
Summary
The transcription factor PRDM1/BLIMP1 is crucial for multiple myeloma (MM) development. Loss of PRDM1/BLIMP1 function prevents plasmacytoma formation, suggesting it
Area of Science:
- Immunology
- Cancer Biology
- Molecular Biology
Background:
- Multiple myeloma (MM) and plasmacytomas are cancers originating from antibody-secreting cells (ASCs).
- PRDM1/BLIMP1 is a key regulator in ASC development, consistently expressed in MM, but its role in B-cell transformation is debated.
- Some diffuse large B-cell lymphomas (DLBCLs) lose PRDM1 expression, implying a potential tumor suppressor function in certain contexts.
Purpose of the Study:
- To investigate the role of PRDM1/BLIMP1 in the transformation of mature B cells.
- To determine the effect of Blimp1 loss on plasmacytoma prevalence, latency, and phenotype using a mouse model.
Main Methods:
- Utilized a plasmacytoma-prone transgenic mouse model to study the impact of Blimp1 gene dosage.
- Assessed plasmacytoma prevalence, latency, and cellular phenotype following alterations in Blimp1 expression.
Main Results:
- Decreasing Blimp1 dosage did not alter plasma cell numbers in non-transgenic mice.
- Significantly reduced plasmacytoma prevalence was observed in transgenic mice with altered Blimp1 dosage.
- Complete loss of functional Blimp1 abolished plasmacytoma formation in the studied model.
Conclusions:
- PRDM1/BLIMP1 is essential for plasma cell transformation, acting as a limiting factor.
- These findings highlight PRDM1/BLIMP1 as a potential therapeutic target for multiple myeloma and related cancers.
